Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association

Authors, Journal, Affiliations, Type, DOI

• Craig J. Beavers, Jo E. Rodgers, Aaron J. Bagnola, Theresa M. Beckie, Umberto Campia, Katherine E. Di Palo, Tochi M. Okwuosa, Eugene R. Przespolewski, Susan Dent; on behalf of the AHA Clinical Pharmacology Committee and Cardio-Oncology Committee
• Circulation, 2022;145:e811–e838
• Affiliations: University of Kentucky, UNC Eshelman School of Pharmacy, Ohio State Wexner Medical Center, University of South Florida, Brigham and Women's Hospital/Harvard, Montefiore Medical Center, Rush University Medical Center, Roswell Park Comprehensive Cancer Center, Duke Cancer Institute
• Type: AHA Scientific Statement
• DOI: 10.1161/CIR.0000000000001056

Overview

This AHA Scientific Statement is a comprehensive clinical reference for drug-drug interactions (DDIs) in the cardio-oncology population, covering both pharmacodynamic (PD) and pharmacokinetic (PK) mechanisms. PD interactions are mapped to six cardiovascular toxicity domains — hypertension, CTRCD, ICI myocarditis, VTE, bleeding, and QT prolongation/arrhythmias. PK interactions are catalogued by metabolic enzyme and transporter (CYP1A2, 2C8, 2C9, 2C19, 2D6, 3A4, P-gp, UGT) with four comprehensive reference tables. DDI risk in this population is amplified by narrow therapeutic indices, complex polypharmacy, and wide interpatient variability in drug metabolism from age, sex, genetics, and comorbidities.

Keywords

AHA Scientific Statements; cardiovascular system; drug interactions; medical oncology; pharmacokinetics; pharmacology

Key Takeaways

Types of Drug Interactions

• Pharmacodynamic interactions: one drug alters the pharmacological effect of another through additive, synergistic, or antagonistic mechanisms — no change in drug concentrations required.
• Pharmacokinetic interactions: one drug alters the absorption, distribution, metabolism, or excretion of another, resulting in altered serum concentrations.
• Pharmaceutical interactions: physical/chemical incompatibility — e.g., paclitaxel in polyoxyethylated castor oil solvent entraps doxorubicin, reducing its distribution volume and increasing cardiotoxicity. Sequential taxane-then-anthracycline administration is required.

Pharmacodynamic Interactions — Hypertension

• VEGF inhibitors (anti-VEGF TKIs, VEGF decoy receptors, anti-VEGF mAbs): most common cause of cancer therapy-related hypertension (21–40% in first-time users). VEGF inhibitor–induced hypertension is a marker of treatment response; BP control improves both cancer prognosis and CV outcomes.
• First-line antihypertensives with VEGF inhibitors: ACE inhibitors/ARBs (renoprotection; meta-analysis 11 trials, n=4,964: disease-free survival HR 0.60, OS HR 0.75). Second-line: dihydropyridine CCBs (amlodipine/felodipine preferred — less CYP3A4 interaction; strongest data for BP control with anti-VEGF TKIs). Long-acting nitrates effective for refractory cases but may theoretically impair VEGF-mediated angiogenesis.
• Abiraterone + prednisone: Hypertension 3.3–36.7%; incidence higher with prednisone 5 mg once daily vs. twice daily (32.4% vs. 16.5%). Prophylactic low-dose prednisone recommended to prevent mineralocorticoid excess.
• mTOR inhibitors (everolimus/temsirolimus) + aromatase inhibitors: Grade 3–4 hypertension 10% (BOLERO-4) to 16% (BELLE-3).
• NSAIDs: All NSAIDs at anti-inflammatory doses raise BP in normo- and hypertensive patients. Replace with acetaminophen; if NSAID unavoidable, monitor BP regularly.
• Steroids + cancer therapy: Additive hypertension; diuretics and antihypertensives may be required.

Pharmacodynamic Interactions — Cardiomyopathy (CTRCD)

• Anthracyclines + anti-HER2 agents ± taxanes ± cyclophosphamide: Sequential use of anthracyclines and trastuzumab is mandatory — concurrent use produces >7-fold increased HF risk. Original trastuzumab trials: cardiomyopathy in 27% of patients receiving concurrent anthracycline + cyclophosphamide + trastuzumab vs. 3–7% with trastuzumab alone.
• Cumulative dose thresholds: Doxorubicin >240 mg/m² prior to trastuzumab → 3-fold increased cardiotoxicity risk; >250 mg/m² classified as high-risk threshold. FDA dexrazoxane threshold: >300 mg/m². Taxane–anthracycline combination: 420 mg/m² anthracycline → up to 50% HF incidence vs. 5.4% at <360 mg/m² (from taxane-mediated PK increase in doxorubicin exposure).
• Dual HER2 blockade (trastuzumab + pertuzumab): Standard of care; does not increase cardiotoxicity beyond single-agent trastuzumab.
• Cardioprotective strategies: Dexrazoxane (IIa — FDA approved for metastatic breast cancer >300 mg/m² doxorubicin); liposomal doxorubicin; continuous infusion; ACE-I + beta-blockers for high/VH risk patients.

Pharmacodynamic Interactions — ICI Myocarditis

• Combination ICI (anti-CTLA-4 + anti-PD-1): 4.7-fold increased myocarditis risk vs. single ICI; overall incidence 0.04–1.14%; mortality 25–50%.
• ICI + TKIs (BRAF/MEK inhibitors, axitinib + pembrolizumab): Cardiomyocyte sensitization to ICI-mediated inflammation postulated; myocarditis reported within 15 days of combination initiation.
• Management: Prompt ICI discontinuation → first-line corticosteroids → second-line tacrolimus/mycophenolate/ATG/infliximab/abatacept/tofacitinib (investigational).

Pharmacodynamic Interactions — Thromboembolism

• IMiDs (thalidomide/lenalidomide/pomalidomide) + dexamethasone ± doxorubicin: VTE risk dose-dependent; corticosteroids sensitize cells to IMiD-driven release of thrombogenic cytokines (tissue factor, von Willebrand factor, factor VIII). High-dose dexamethasone ≥480 mg/cycle highest risk; even 160 mg/cycle elevated in newly diagnosed MM. Prophylaxis: LMWH for newly diagnosed MM; low-dose aspirin for others.
• SAVED and IMPEDE VTE scores validated specifically for myeloma patients on IMiD-based regimens.
• Pegaspargase + prednisone ± doxorubicin (in ALL induction): VTE from antithrombin depletion + platelet sensitization. Dexamethasone preferred over prednisone — lower VTE during induction. Oral contraceptives must be discontinued throughout pegaspargase therapy.
• Ponatinib: Multikinase inhibition (VEGF + PDGFR) → high arterial thrombosis risk; aspirin prophylaxis required (Italian retrospective data). LMWH for inpatients; select antifungals increase ponatinib levels via CYP3A4 → theoretical potentiation of thrombotic risk.

Pharmacodynamic Interactions — Bleeding

• Ibrutinib (BTK inhibitor): AF incidence 3.5–16% (RR 4.69; meta-analysis n=2,580) mandating anticoagulation; paradoxically causes major bleeding via Btk/Tec platelet dysfunction. DAPT raises major bleeding 40–50% with ibrutinib. Acalabrutinib and evobrutinib have lower bleeding risk (off-target Src inhibition not observed).
• Bevacizumab: Severe (>grade 3) pulmonary hemorrhage 1.2–1.9% in NSCLC trials; more common in squamous histology. Increased GI/GU/CNS bleeding in combination therapy.
• Warfarin + 5-fluorouracil/capecitabine: Fluoropyrimidines inhibit CYP2C9 → markedly increased warfarin sensitivity; grade 4–5 interaction — avoid concurrent use; frequent PT/INR monitoring mandatory if unavoidable.
• DOACs in cancer-associated VTE: DOACs preferred over LMWH for non-GI malignancy (CARAVAGGIO: apixaban 3.8% vs. dalteparin 4.0% major bleeding). Avoid DOACs in GI malignancy (higher GI bleeding vs. LMWH). Limited safety data for CNS malignancies, post-cancer surgery, thrombocytopenia, hematologic cancers.
• DAPT post-PCI in cancer: Shorter durations recommended for thrombocytopenia <50,000/μL — 2 weeks (balloon angioplasty), 4 weeks (bare metal stent), 3–6 months (drug-eluting stent).

Pharmacodynamic Interactions — QT Prolongation and Arrhythmias

• Highest QT risk cancer drugs (Table 2 from source):
  • Arsenic trioxide: >10% QTc prolongation, TdP cases, sudden death reports — FDA boxed warning
  • Vandetanib: >10% QTc prolongation, TdP + — FDA boxed warning
  • Lapatinib: >10% QTc prolongation — FDA warning
  • Nilotinib: 1–10%, TdP + — FDA boxed warning
  • Pazopanib, sunitinib: 1–10%, TdP + — FDA warnings
  • Ribociclib, vemurafenib, crizotinib: 1–10% QTc — FDA warnings
  • Panobinostat (HDAC inhibitor): 1–10%, boxed warning
• Additive bradycardia: ceritinib/crizotinib + β-blockers, non-DHP CCBs (verapamil/diltiazem), or digoxin.
• Fridericia formula (QTcF) preferred over Bazett for QTc correction in cancer patients.
• Ribociclib: morning dosing reduces QTc risk; avoid with strong CYP3A4 inhibitors and tamoxifen (synergistic QTc).
• Tisdale risk score (developed in general hospitalized patients): low score (<7) → 15% QTc prolongation incidence; high score (≥11) → 73% — not yet validated in cancer populations.
• Risk reduction: correct electrolytes (K⁺, Mg²⁺, Ca²⁺), avoid concurrent QT-prolonging supportive care agents (antiemetics chlorpromazine/domperidone/ondansetron; antibiotics azithromycin/clarithromycin/fluoroquinolones; antipsychotics haloperidol/citalopram).

Pharmacokinetic Interactions — Metabolism Overview

• CYP enzymes metabolize ~2/3 of all drugs. Key enzymes: CYP3A4 (most important), CYP2D6. Phase 2: UGT enzymes (UGT1A1 critical for irinotecan/belinostat/etoposide).
• Inhibition → increased substrate AUC → toxicity. Induction → decreased AUC → reduced efficacy.
• Prodrug exception: For drugs requiring CYP activation (clopidogrel via CYP2C19, cyclophosphamide via CYP2C9), CYP inhibition reduces efficacy; induction increases toxicity.

Pharmacokinetic Interactions — CYP3A4

• CV substrates: amiodarone, dronedarone, dofetilide, apixaban, rivaroxaban, edoxaban (<4%), atorvastatin, lovastatin, simvastatin, sirolimus, tacrolimus, amlodipine, eplerenone, ticagrelor, sildenafil/tadalafil, colchicine.
• Oncology strong inhibitors (+++): idelalisib — avoid apixaban; dose-reduce rivaroxaban; monitor dabigatran; no adjustment for edoxaban.
• Oncology strong inducers (+++): enzalutamide, apalutamide, mitotane, dabrafenib, vemurafenib — apixaban/rivaroxaban + enzalutamide: avoid (enzalutamide simultaneously a CYP3A4 inducer AND P-gp inhibitor — complex net effect).
• CV diltiazem/verapamil (strong CYP3A4 inhibitors): increase many TKI concentrations significantly.
• Statin management: Switch simvastatin/lovastatin → pravastatin (preferred), fluvastatin, or rosuvastatin when strong CYP3A4 inhibitors are used.

Pharmacokinetic Interactions — P-glycoprotein

• CV P-gp substrates: dabigatran, digoxin, edoxaban, rivaroxaban, apixaban (minimal), atorvastatin, losartan, labetalol, propranolol.
• CV P-gp inhibitors: amiodarone (+++), dronedarone (+++), carvedilol (+++), verapamil (+++), nicardipine (+++).
• Oncology P-gp inhibitors: venetoclax, tucatinib, ibrutinib, lapatinib, sorafenib, sunitinib, abemaciclib, palbociclib.
• Digoxin–anthracycline: 50% reduction in digoxin absorption with anthracyclines (P-gp upregulation + intestinal epithelial toxicity). Liposomal anthracyclines cause less induction. Monitor digoxin levels.
• Tucatinib: increases rivaroxaban/apixaban bleeding risk via P-gp inhibition → prefer edoxaban (P-gp only, not CYP3A4 substrate).
• Venetoclax: CYP3A4 + P-gp substrate AND P-gp inhibitor — dose reduction required with P-gp inhibitors (carvedilol, ranolazine) and moderate CYP3A4 inhibitors (diltiazem, conivaptan).

Pharmacokinetic Interactions — DOACs

• Apixaban + rivaroxaban: dual CYP3A4 + P-gp substrates → most susceptible to DDIs.
• Dabigatran + edoxaban: P-gp only (not CYP3A4) → fewer interactions; edoxaban has least interaction risk overall.
• Rule: If dual moderate/strong CYP3A4 + P-gp inhibitor → avoid apixaban/rivaroxaban. Recommendations differ per DOAC and per specific cancer agent — must check each combination individually.
• DOACs have no validated serum monitoring assay for routine clinical use.

Pharmacokinetic Interactions — Tamoxifen

• Tamoxifen requires CYP2D6 (and CYP3A4) metabolism to its most potent active metabolite, endoxifen. Strong CYP2D6 inhibitors reduce endoxifen and may reduce efficacy.
• CV agents that inhibit CYP2D6: amiodarone, labetalol, hydralazine, select CCBs (diltiazem, verapamil, felodipine).
• Antidepressant CYP2D6 inhibitors by degree: strong — bupropion, fluoxetine, paroxetine; moderate — duloxetine, fluvoxamine; mild — citalopram, escitalopram, sertraline. Preferred (minimal inhibition): mirtazapine, trazodone, venlafaxine.

Pharmacokinetic Interactions — Warfarin

• Warfarin (CYP2C9 major substrate, CYP3A4 minor): many cancer therapies inhibit CYP2C9 → increased warfarin/bleeding risk.
• Avoid warfarin + fluoropyrimidines (capecitabine/5-FU) — grade 4–5 interaction; switch to DOAC or LMWH.
• Avoid warfarin + tamoxifen — CYP2C9 inhibition.
• Close PT/INR monitoring with moderate interactions: carboplatin, doxorubicin, vincristine, TKIs (ibrutinib, imatinib).

Pharmacokinetic Interactions — Supportive Care

• Antibiotics: azithromycin (minimal CYP3A4) preferred over clarithromycin/erythromycin (strong CYP3A4 inhibitors) when TKIs co-prescribed.
• Antifungals: fluconazole (less CYP3A4) preferred over other azoles; select azoles increase ponatinib concentrations.
• Acetaminophen: maximum daily dose should be reduced with dasatinib, imatinib, sunitinib — these TKIs undergo glucuronidation; hepatotoxicity risk at high doses.
• TKI + opioids: select combinations increase opioid concentrations (imatinib/nilotinib + fentanyl; imatinib + hydrocodone/oxycodone; gefitinib + tramadol) — monitor for sedation/constipation.
• Acid suppression (PPI/H2-blockers): Weak-base TKIs (dasatinib, ibrutinib, imatinib) require acidic environment for absorption — check prescribing information for each TKI to determine avoidance vs. separate administration.
• UGT1A1 inhibitors (gemfibrozil, atazanavir): increase SN-38 (active irinotecan metabolite) levels → severe neutropenia; avoid with irinotecan/sacituzumab.

Limitations of the Document

• Not exhaustive — clinicians should consult multiple DDI databases; considerable variability exists between screening databases.
• Most cancer drugs are approved before all DDIs are fully characterised — relevant DDIs may be unrecognised at market approval.
• Interpatient variability (age, sex, genetics, comorbidities) limits DDI predictions; genetic polymorphisms in CYP2D6/2C19/2C9 can significantly alter individual responses.
• Routine pharmacogenomic testing for CYP polymorphisms is not yet validated for DDI management in oncology.
• Management recommendations must be applied with clinical judgement about severity of interaction and available alternatives.

Key Concepts Mentioned

• concepts/Cardio-Oncology — discipline framework within which all DDIs are managed
• concepts/Cancer-Therapy-Related-CV-Toxicity — pharmacodynamic DDIs mapped to all major cardiotoxicity syndromes
• concepts/Torsades-de-Pointes — detailed QT risk table by cancer drug class (Table 2)
• concepts/Drug-Induced-Arrhythmia — arrhythmia risk including QT prolongation, bradycardia, AF in cancer therapy context
• concepts/DAPT-Strategies — DAPT shortening in cancer patients post-PCI and ibrutinib interactions

Key Entities Mentioned

• entities/Atrial-Fibrillation — ibrutinib-associated AF (RR 4.69); anticoagulation DDIs; DAPT bleeding risk with ibrutinib
• entities/Heart-Failure — CTRCD from anthracycline + HER2 combinations; DOACs in cancer-associated VTE

Wiki Pages Updated

• wiki/sourceindex.md — source pointer added
• wiki/concepts/Cancer-Therapy-Related-CV-Toxicity.md — DDI section added
• wiki/concepts/Torsades-de-Pointes.md — cancer QT drug table (Table 2) expanded
• wiki/concepts/Cardio-Oncology.md — DDI domain reference added